Faculty Information - Ryo Tanaka

（Last updated : 2024-05-23 16:04:56）

Ryo Tanaka
Department Kawasaki Medical School Kawasaki Medical School, Department of Dermatology,

Position Associate Professor

■ Journal

1.	2023/01/11	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
2.	2022/10/01	Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
3.	2021/12	Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
4.	2021/11	Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
5.	2018/07	Benign cephalic histiocytosis: A case with some infiltrate of CD1a positive langerin negative cells
6.	2018	Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses
7.	2017/09	Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
8.	2017	Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with myasthenia gravis as an immune-related adverse event
9.	2015/06	Photoletter to the editor: Pigmented dermatofibrosarcoma protuberans in a 4-year-old girl and ultrasonographic findings.
10.	2015/02	Zoonotic onchocerciasis.
11.	2015/01	Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome.
12.	2014/05	Tumor necrosis factor-alpha and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A
13.	2014/01	Epigenetic biomarkers in skin cancer.
14.	2011/09	Prognostic molecular biomarkers for cutaneous malignant melanoma.
15.	2011/05	Molecular mechanisms of metastasis
16.	2011/03	Penile verrucous carcinoma arising in HPV-negative condylomatous papules.
17.	2009/12	Remission of sublamina densa-type linear IgA bullous dermatosis after Helicobacter pylori eradication
18.	2009/08	Sentinel lymph node detection in skin cancer using fluorescence navigation with indocyanine green.
19.	2007/05	A novel fusion gene of collagen type I alpha 1 (exon 31) and platelet-derived growth factor B-chain (exon 2) in dermatofibrosarcoma protuberans.
20.	2007/01	Clinical utility of an interferon-γ-based assay for mycobacterial detection in papulonecrotic tuberculid.
21.	2005/01	Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.
22.	2004/02	Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma.
23.	2004	Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.
24.	2001/12	Numerical, morphological and phenotypic changes in Langerhans cells in the course of murine graft-versus-host disease
Display 5 items
Display all(24)

■ Presentation

1.	2018/01/27	BNCT for vulvar melanoma and extramammary Paget's disease of the genital regions. （Speech，General）
2.	2017/10	Successful reinstitution of nivolumab in combination with corticosteroids for metastaticmalignant melanoma with diverse immune-related adverse events including severe hemolytic anemia （Poster notice，General）
3.	2014/04/06	Tumor necrosis factor-alpha and apoptosis induction in melanoma cells through histones modification by 3-deazaneplanocin A （Poster notice，General）